Free Republic

Early data for Roche Holding AG's drug Avastin shows enough promise in treating patients with a certain brain cancer to be considered for quick approval, a U.S. advisory panel said on Tuesday. The drugmaker is seeking accelerated approval to market the drug for patients diagnosed with a recurrence of the particularly deadly disease after trying other therapies first. The drug, made by its recently acquired Genentech unit, is already used to treat lung, colon and breast cancers. Data from two early studies showed enough of a response in patients whose disease did not advance and some whose tumors decreased in...

It took only an instant for 58-year-old Gailanne Reeh to go from the picture of health to death's door. By chance, her doctor noticed a lump under her arm during a routine exam. It turned out to be advanced breast cancer... --snip-- What does it mean to say an expensive drug works? Is slowing the growth of tumors enough if life is not significantly prolonged or improved? How much evidence must there be before billions of dollars are spent on a drug? Who decides? When, if ever, should cost come into the equation? --snip-- Mr. Lemieux, who was a sales...

Marion Kleinfeld got up one Sunday morning, picked up the newspaper, settled down to read it, and couldn't see the words. Kleinfeld, 79, of Delray Beach, Fla., already blind in her right eye, lost sight in her other eye because of a condition called wet age-related macular degeneration, AMD, the leading cause of blindness in people over 55. Leaking blood vessels in the back of the eye cause a large black spot in the center of vision. "I could not see at all. It was very frightening," she said. After years of having to tell patients losing their eyesight to...

ASSOCIATED PRESS WASHINGTON -- The first drug shown to significantly improve the vision of patients threatened by a major cause of blindness in the elderly won federal approval Friday. The drug, called Lucentis, treats the wet form of age-related macular degeneration, a disorder where blood vessels behind the retina leak blood and fluid, worsening vision and often causing blindness. An estimated 90 percent of the 1.4 million Americans who have lost their eyesight due to the disorder have the wet form. Lucentis, made by Genentech, Inc., a South San Francisco, Calif., biotechnology company, inhibits the growth of blood vessels when...